Compare Orchid Chemicals with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs AUROBINDO PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD AUROBINDO PHARMA ORCHID PHARMA LTD/
AUROBINDO PHARMA
 
P/E (TTM) x -0.5 11.0 - View Chart
P/BV x 0.1 2.4 4.9% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ORCHID PHARMA LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
AUROBINDO PHARMA
Mar-18
ORCHID PHARMA LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs194809 24.0%   
Low Rs35504 6.9%   
Sales per share (Unadj.) Rs276.5281.1 98.4%  
Earnings per share (Unadj.) Rs-79.241.4 -191.5%  
Cash flow per share (Unadj.) Rs-43.550.9 -85.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs53.9199.4 27.1%  
Shares outstanding (eoy) m70.45585.88 12.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.42.3 17.7%   
Avg P/E ratio x-1.415.9 -9.1%  
P/CF ratio (eoy) x-2.612.9 -20.4%  
Price / Book Value ratio x2.13.3 64.5%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m8,067384,630 2.1%   
No. of employees `0002.817.3 16.2%   
Total wages/salary Rs m2,52721,308 11.9%   
Avg. sales/employee Rs Th6,956.19,500.7 73.2%   
Avg. wages/employee Rs Th902.51,229.4 73.4%   
Avg. net profit/employee Rs Th-1,993.01,397.9 -142.6%   
INCOME DATA
Net Sales Rs m19,477164,666 11.8%  
Other income Rs m4071,020 39.9%   
Total revenues Rs m19,884165,686 12.0%   
Gross profit Rs m1,10337,718 2.9%  
Depreciation Rs m2,5195,580 45.1%   
Interest Rs m5,227777 672.5%   
Profit before tax Rs m-6,23632,380 -19.3%   
Minority Interest Rs m2031 62.7%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1258,183 -1.5%   
Profit after tax Rs m-5,58024,229 -23.0%  
Gross profit margin %5.722.9 24.7%  
Effective tax rate %2.025.3 7.9%   
Net profit margin %-28.714.7 -194.7%  
BALANCE SHEET DATA
Current assets Rs m11,014121,878 9.0%   
Current liabilities Rs m32,06086,806 36.9%   
Net working cap to sales %-108.121.3 -507.3%  
Current ratio x0.31.4 24.5%  
Inventory Days Days95130 73.1%  
Debtors Days Days3468 49.1%  
Net fixed assets Rs m29,44081,037 36.3%   
Share capital Rs m705586 120.2%   
"Free" reserves Rs m2,043116,218 1.8%   
Net worth Rs m3,800116,804 3.3%   
Long term debt Rs m9,0184,512 199.9%   
Total assets Rs m46,510211,052 22.0%  
Interest coverage x-0.242.7 -0.5%   
Debt to equity ratio x2.40 6,143.6%  
Sales to assets ratio x0.40.8 53.7%   
Return on assets %-0.811.8 -6.4%  
Return on equity %-146.920.7 -708.0%  
Return on capital %-3.727.4 -13.7%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51380,727 9.3%   
Fx outflow Rs m5,64934,700 16.3%   
Net fx Rs m1,86546,027 4.1%   
CASH FLOW
From Operations Rs m1,68219,548 8.6%  
From Investments Rs m-9,860-19,570 50.4%  
From Financial Activity Rs m6,6448,642 76.9%  
Net Cashflow Rs m-1,5358,922 -17.2%  

Share Holding

Indian Promoters % 32.3 54.1 59.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.0 57.9%  
FIIs % 3.3 27.7 11.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 10.2 542.2%  
Shareholders   84,811 69,601 121.9%  
Pledged promoter(s) holding % 54.9 8.6 641.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  ELDER PHARMA  GSK PHARMA  DR. DATSONS LABS  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS